FOY-305-01:FOY-305 Phase 3(COVID-19)

JRCT ID: jRCT2031200198

Registered date:12/11/2020

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: SARS-CoV-2 Infectious Disease (COVID-19)
• Date of first enrollment: 09/11/2020
• Target sample size: 110
• Study type: Interventional
• Intervention(s): FOY-305 600 mg or placebo will be orally administered 4 times daily, before breakfast, before lunch, before evening meal, and at bedtime.

Outcome(s)

• Primary Outcome: Time to SARS-CoV-2 negative test

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

1. Inpatient or outpatient: Inpatient
2. Positive SARS-CoV-2 test by a method eligible for definitive diagnosis
3. Enrollment in this study within 5 days after onset of symptoms of SARS-CoV-2 infection (COVID-19) (for asymptomatic patients, enrollment in this study within 5 days after collection of the sample that tested positive)

Exclude criteria

1. Receiving oxygen therapy
2. Difficulty in swallowing oral medication
3. History of COVID-19
4. History of vaccination against COVID-19
5. Taking camostat mesilate

Related Information

• Primary Sponsor: Osawa Masahiro
• Secondary ID(s): NCT04657497